Next Article in Journal
Nanotechnology for Cancer Therapy Based on Chemotherapy
Next Article in Special Issue
Synthesis and Tuberculostatic Activity Evaluation of Novel Benzazoles with Alkyl, Cycloalkyl or Pyridine Moiety
Previous Article in Journal
A Serendipitous Journey Leading to My Love of Dendritic Patterns and Chemistry
Previous Article in Special Issue
In Vitro Anti-Toxoplasma gondii and Antimicrobial Activity of Amides Derived from Cinnamic Acid
Communication

Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis

1
Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany
2
Research Center of Borstel, Leibniz Lung Center, 23845 Borstel, Germany
3
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel, 23845 Borstel, Germany
4
Department of Medical Microbiology, University of Szeged, 6720 Szeged, Hungary
*
Author to whom correspondence should be addressed.
Molecules 2018, 23(4), 825; https://doi.org/10.3390/molecules23040825
Received: 23 February 2018 / Revised: 26 March 2018 / Accepted: 1 April 2018 / Published: 4 April 2018
The number of effective first-line antibiotics for the treatment of Mycobacterium tuberculosis infection is strongly limited to a few drugs. Due to emerging resistance against those drugs, second- and third-line antibiotics have been established in therapy with certain problems and also increasing mycobacterial resistance. An alternative to such novel drugs or combined therapeutic regimes which may reduce resistance development is finding enhancers of mycobacterial drug effectiveness, especially enhancers that counteract causative resistance mechanisms. Such enhancers may reduce the extracellular drug efflux mediated by bacterial efflux pumps and thus enhance the intracellular drug toxicity. We developed novel 1,4-dihydropyridines (DHPs) as potential efflux pump inhibitors with some determined P-gp affinities. The influence on the antituberculotic drug toxicity has been investigated for three prominent antituberculotic drugs. Exclusive and selective toxicity enhancing effects have been detected for isoniazid (INH) which could be related to certain substituent effects of the 1,4-DHPs. So, structure-dependent activities have been found. Thus, promising enhancers could be identified and a suggested efflux pump inhibition is discussed. View Full-Text
Keywords: antibacterial enhancing activity; synthesis; derivatives; structure-activity; lead structure antibacterial enhancing activity; synthesis; derivatives; structure-activity; lead structure
Show Figures

Scheme 1

MDPI and ACS Style

Lentz, F.; Reiling, N.; Martins, A.; Molnár, J.; Hilgeroth, A. Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis. Molecules 2018, 23, 825. https://doi.org/10.3390/molecules23040825

AMA Style

Lentz F, Reiling N, Martins A, Molnár J, Hilgeroth A. Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis. Molecules. 2018; 23(4):825. https://doi.org/10.3390/molecules23040825

Chicago/Turabian Style

Lentz, Fabian, Norbert Reiling, Ana Martins, Joseph Molnár, and Andreas Hilgeroth. 2018. "Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis" Molecules 23, no. 4: 825. https://doi.org/10.3390/molecules23040825

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop